• Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.

    血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。

    youdao

  • Objective To assess the clinical significance of plasma t-PA, PAI-1 in acute cerebral infarction.

    目的探讨血浆组织型纤溶酶原激活物(t -PA)及其抑制物(PAI - 1)在急性脑梗死发病中的意义。

    youdao

  • Objective To investigate effects of fibrinolytic system upon deep venous thrombosis, focused on PLG, t-PA and PAI-1.

    目的以纤溶酶原、t - PA和PAI - 1为轴心,探讨纤溶系统对深静脉血栓形成(DVT)的影响。

    youdao

  • Conclusion In Vitro, high glucose suppresses human fibroblast cell proliferation and stimulates PAI-1 gene expression.

    结论高糖可抑制成纤维细胞增殖,刺激PAI - 1的表达。

    youdao

  • There were significant positive correlations between PAI-1 and WHR, TG, GSP, FINS and UA in the youth and middle-age group.

    仅在青中年组与PAI-1表现相关性的指标是腰臀比(WHR)、甘油三酯(TG)、糖化血清蛋白(GSP)、血尿酸(UA)和FINS。

    youdao

  • Objective To investigate the influence of rosiglitazone on blood lipids and plasma PAI-1 activity in type 2 diabetic patients.

    目的观察罗格列酮对2型糖尿病患者血脂水平和血浆纤溶酶原激活物抑制剂1 (PAI - 1)活性的影响。

    youdao

  • The expression of PAI-1 in liver tissue relates with activity HSCs. It reflects the development of liver fibrosis but not the degree.

    肝组织中PAI - 1的表达与星状细胞活化有关,可反映肝纤维化的进展,但不能反映肝纤维化程度。

    youdao

  • The experiments of inhibiting heterogeneous adhesion and invasion were used to observe the role of PAI-1 in PNC's metastasis and invasion.

    使用异质粘附、侵袭抑制实验观察PAI-1在鼻咽癌细胞侵袭和转移过程中的作用。

    youdao

  • The cardioprotective and renoprotective properties of some currently available drugs might be attributable in part to inhibition of PAI-1.

    目前一些药物的心血管系统保护和肾脏保护的特点部分是源于其对PAI - 1活性的抑制作用。

    youdao

  • This paper had summarized the structure, distribution, activity, expression of PAI-1 and the relation of its level with cerebral embolism.

    文章概述了PAI - 1的结构、分布、活性及其表达,以及PAI - 1水平同脑血栓的关系。

    youdao

  • Results There were significant differences int-PA and PAI-1 levels between the normal group and different types of cancer patients(P<0.05).

    结果不同类型的恶性肿瘤患者t-PA及PAI-1与健康对照组比较差异有统计学意义(P<0.05)。

    youdao

  • Objective To investigate the effect of simvastatin, ticlopidin and aspirin on the plasma plasminogen activitor inhibitor-l(PAI-1) contents in CHD patients.

    目的研究辛伐他汀、抵克立得、阿司匹林对冠心病(CHD)患者血浆PAI-1含量的影响。

    youdao

  • Method Plasminogen activator inhibitor-1(PAI-1) in 33 cases of diabetic nephropathy and 30 healthy controls were detected, and the test results were observed.

    方法:检测33例糖尿病肾病患者及30例健康体检对照组血浆纤溶酶原激活物抑制物-1(PAI-1),观察检测结果。

    youdao

  • AIM: To observe the effect of extract of Ginkgo biloba leaves on plasminogen activator inhibitor 1(PAI-1)and thromboxane B2(TXB-2)in type 2 diabetes mellitus(DM).

    目的:观察银杏叶提取物对2型糖尿病病人纤溶酶原激活物抑制物1(PAI 1)及凝血烷B2(TXB 2 )的影响。

    youdao

  • Plasminogen activator inhibitor-1 (PAI-1) is one of the important components of the plasma fibrinolytic system and plays an key role in maintaining its stability.

    纤溶酶原激活物抑制物1 (PAI - 1)是血浆纤维蛋白溶解系统的重要组成物之一,对维持血浆纤溶系统的稳定起重要作用。

    youdao

  • Conclusion Hypertension, increased plasma PAI-1 activity, fibrinogen level and plasma Hcy level are the important risk factors in the recurrent cerebral infarction.

    结论:高血压、血纤溶系统活性升高、高水平纤维蛋白原、高同型半胱氨酸血症是脑梗死再发的重要危险因素。

    youdao

  • The PAI-1 obvious correlates with the IS and CP. The increasement of PAI-1 causing reduction of serum plasminogen activator might be a intermediate process of IR and CBI.

    脑梗塞血浆PAI-1活性增高与IS及C肽呈正相关,PAI-1活性增高导致血浆纤溶活性降低,可能是IR引起脑梗塞的中间环节。

    youdao

  • Results: The activity of PAI-1 was higher and t-PA was lower in patients with coronary heart disease, and this difference is also found between Type a and Non Type a patients.

    结果:冠心病患者比正常人群的PAI - 1活性上升,t -PA活性下降;这种改变在不同行为类型之间比较,A型行为类型比非a型行为类型的冠心病患者PAI - 1的活性升高而t - PA活性降低。

    youdao

  • The neurological defect scores in patients with acute cerebral thrombosis were positively correlated with plasma and cerebrospinal fluid concentrations oft-PA and PAI-1 antigen.

    脑血栓形成组病人神经功能缺损评分与血浆及脑脊液t -PA、PAI -1抗原含量呈正相关。

    youdao

  • ObjectiveTo study the role and significance of plasminogen activator inhibitor-1(PAI-1) in renal fibrosis(RF) after damage and elucidate the molecular pathogenetic mechanisms of RF.

    为探讨纤溶酶原激活物抑制因子1(PAI 1)在肾损伤后纤维化中的作用和意义,揭示其发病的分子病理机制。

    youdao

  • Objective to study the effects of transient cerebral ischemic reperfusion (IR) and flunarizine on the expression of plasminogen activator inhibitor-1 (PAI-1) protein in brain tissue of gerbils.

    目的研究沙鼠脑缺血再灌注后脑内1型纤溶酶原激活物抑制剂(PAI - 1)蛋白表达变化,以及西比灵干预的影响。

    youdao

  • We have a study on the relationship between PAI-1 and the recent prognosis of patients with NSTE-ACS and the conventional factors being significant to the recent prognosis of patients with NSTE-ACS.

    应用发色底物法测定所有患者血浆PAI-1的活性,并分析其与NSTE-ACS患者近期预后及预后相关因素之间的关系。

    youdao

  • Objective To study the expression of plasminogen activator inhibitor-1(PAI-1) of the blood serum and plaques in atherosclerotic rabbits in order to explore the effect of PAI-1 on atherosclerosis (AS).

    目的通过对动脉粥样硬化(AS)兔血清和粥样硬化斑块中纤溶酶原激活物抑制物-1(PAI-1)表达的研究,探讨PAI-1在AS中的作用。

    youdao

  • Objective To investigate the relationship between the plasminogen activator inhibitor 1(PAI 1) promotor region gene polymorphism and cerebral stroke.

    目的探讨纤溶酶原激活物抑制物- 1(PAI- 1)启动子区基因多态性与脑卒中的关系。

    youdao

  • Objective To investigate effects of two proinflammatory cytokines on the production of plasminogen activator inhibitor 1(PAI 1) by human pleural mesothelial cells(HPMC).

    目的研究前炎症细胞因子对人胸膜间皮细胞(HPMC)释放纤溶酶原激活物抑制剂(PAI 1)的诱导效应。

    youdao

  • To investigate the changes of plasma PAI 1 activity and its gene polymorphism in cerebral infarction.

    目的:探讨纤溶酶原激活物抑制物- 1 (PAI - 1)活性变化和其基因多态性对脑梗死及其再梗死发病的关系。

    youdao

  • Conclusion:Pravastatin can not inhibit the secretion of PAI 1 in hepatic cells and the inhibition of hydroxymethylglutaryl coenzyme A reductase may not be related to the secretion of PAI 1.

    结论:普伐他汀不能抑制肝细胞PAI- 1的分泌。羟甲基戊二酰辅酶A还原酶的抑制与PAI- 1分泌可能没有关系。

    youdao

  • Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).

    目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。

    youdao

  • Objective to study the relationship between plasminogen activator inhibitor type 1 (PAI 1) and biological behaviour of hepatocellular carcinoma (HCC).

    目的研究纤溶酶原激活物抑制剂(PAI1)与肝细胞癌(HCC)生物学特性的关系。

    youdao

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定